JPRN-jRCTs032230119
Recruiting
Phase 1
A novel treatment for ulcerative colitis with purastat: A single-center prospective interventional study
Hashimoto Yu0 sites20 target enrollmentJune 7, 2023
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- lcerative colitis
- Sponsor
- Hashimoto Yu
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Ulcerative colitis between the ages of 18 and 85 at the time of enrollment
- •2\) Patients with mild to moderate disease on the Partial Mayo score
- •3\) Patients who understand the contents of the consent document and give free written consent
Exclusion Criteria
- •1\) Those with concurrent infectious or drug\-induced enteritis
- •2\) Pregnant or possibly pregnant
- •3\) Those who are breast\-feeding
- •4\) Patients with abnormal blood coagulation function
- •5\) Patients with severe organ failure
- •6\)History of hypersensitivity to peptide or protein preparations6\) Other patients who are deemed unsuitable for registration by the physician in charge.
- •7\)Those who are deemed unsuitable for registration by the physician in charge
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Improvement of treatment in ulcerative colitis, severe case and moderate case close to severe case, by early use of infliximabJPRN-UMIN000020402IBD Relapse Prevention Team50
Recruiting
Not Applicable
Better control and treatment of Ulcerative Colitis (UC) by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsiesNL-OMON54471Radboud Universitair Medisch Centrum40
Active, not recruiting
Phase 1
SB012 for the treatment of active ulcerative colitis: a clinical study in early development (phase IIa), conducted in several study centres, with random assignment of patients to active treatment or placebo, to investigate the efficacy, pharmacokinetics, tolerability, and safety of SB012 enema administered once dailyActive ulcerative colitisTherapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]EUCTR2013-004599-36-DEsterna biologicals GmbH & Co. KG18
Active, not recruiting
Phase 1
Probiotic Treatment of Ulcerative Colitis with Trichuris suis ova (TSO)EUCTR2017-004772-65-DKParaTech A/S120
Recruiting
Not Applicable
Study on Treatment of ulcerative colitis with infliximab originator and bio- Similar Targeting remissioulcerative colitisJPRN-UMIN000043098Sapporo Medical University150